Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Neuropharmacology. 2020 Sep 17;180:108296. doi: 10.1016/j.neuropharm.2020.108296

Figure 4. The CRF2 antagonist Astressin 2B alters basal but not CRF-stimulated inhibitory control of male and female CRF1+ CeA neurons.

Figure 4.

(A) Representative voltage-clamp recordings from male (top) and female (bottom) CRF1+ CeA neurons during focal application of aCSF (upper) or Astressin 2B (200nM; lower). (B) Quantification of sIPSC frequency in male and female CRF1+ CeA neurons following aCSF or Astressin 2B (200nM) focal application expressed in Hz (upper left) and percent of control (upper right). Quantification of sIPSC amplitude in male and female CRF1+ CeA neurons following aCSF or Astressin 2B (200nM) focal application expressed in picoamps (lower left) and percent of control (lower right). (C) Representative voltage-clamp recordings from male (top) and female (bottom) CRF1+ CeA neurons during focal application of Astressin 2B (200nM; upper) or Astressin 2B (200nM) plus CRF (200nM) co-application (lower). (D) Quantification of sIPSC frequency in male and female CRF1+ CeA neurons following focal application of Astressin 2B (200nM) and Astressin 2B (200nM) plus CRF (200nM) co-application expressed in Hz (upper left) and percent of control (upper right). Quantification of sIPSC amplitude in male and female CRF1+ CeA neurons following focal application of Astressin 2B (200nM) and Astressin 2B (200nM) plus CRF (200nM) co-application expressed in picoamps (lower left) and percent of control (lower right). * = p < 0.05 by two-way RM ANOVA, # = p < 0.05 by one-sample t-test.